NYSE · AVTR

Avantor, Inc.

$11.76 +$0.32 (+2.80%) 1D After hours

Key Metrics

$7.81B
Market cap
P/E · TTM
$6.55B
Revenue · TTM
−$551.40M
Net income
EPS · TTM $-0.81
Dividend yield
Free cash flow $438.90M
Beta · 1Y 1.30
EBITDA · TTM
Gross margin 32.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 17
    A material event was filed (Form 8-K).

    8-K - Avantor, Inc. (0001722482) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 28
    The stock moved +8.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 28
  • Mar 27
    From its Feb 6 high, the share price fell 34%.

    Peak close $11.26 on Feb 6; trough close $7.41 on Mar 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -34%
  • Feb 11
    The stock moved -13.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 11

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$7.81B
Enterprise value$11.35B
Shares outstanding682.8M
52-wk range$7.27 – $15.93
Avg volume · 20D7.0M
Net cash −$3.54B
Book value / share$8.19
IndustryLaboratory Analytical Instruments
ExchangeNYSE
About Avantor, Inc.
IPO dateMay 17, 2019
Employees13500

Avantor Inc provides products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company operates through two segments: Laboratory Solutions and Bioscience Production.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1.19
P/FCF17.80
EV/EBITDA
EV/Sales1.73
Graham №

Profitability

Gross 32.1%
Operating -7.2%
Net -8.4%
FCF 6.7%
ROE / ROIC -9.6% · -6.0%

Financial Health

Current ratio1.76
Quick ratio1.17
Debt / equity0.68
Debt / EBITDA
Net cash −$3.54B
Working capital$1.04B

Cash Flow · TTM

Operating CF $573.20M
Capex −$134.30M
Free cash flow $438.90M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

1.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings